Study of the minimally invasive proton therapy combined with anti-cancer drugs and vascular disrupting agents

点击翻译按钮获取中文摘要

The aim of this study was to develop combined treatments between proton therapy and chemotherapy using a vascular targeting agent or an anti-cancer drug which not only kill radio-resistant hypoxia tumor cells effectively but also reduce side effects. We used the novel vascular disrupting agent AVE8062 as a vascular targeting agent, while cisplatin was used as an anti-cancer drag. The results of the therapeutic experiments on a murine solid tumor showed that the proton therapy combined with AVE8062 or cisplatin inhibited tumor growth significantly in comparison to their monotherapies.